New Study Identifies Genetic Markers That Predict Treatment Response in Juvenile Arthritis Patients

Breakthrough research may lead to faster, more personalized treatment strategies for children with JIA
By Myra Fonville

A new study conducted by researchers at University College London (UCL) and Great Ormond Street Hospital (GOSH), as part of the CLUSTER Consortium, has identified a group of genes that may help predict which children with juvenile idiopathic arthritis (JIA) will respond favorably to methotrexate (MTX) one of the most commonly prescribed first-line treatments for the condition.

Published in the Annals of the Rheumatic Diseases (2025), the study offers new hope for improving precision medicine in pediatric rheumatology.

Researchers collected blood samples from 97 children in the UK diagnosed with JIA and analyzed the gene expression profiles using RNA sequencing (RNAseq). They focused specifically on genes involved in the interferon pathway, which plays a key role in regulating immune system activity.

They discovered that:

• Children with higher activity of interferon-driven genes before treatment were significantly more likely to respond well to methotrexate.
• Children with lower expression of these genes had a reduced likelihood of benefiting from the medication.

These findings were validated in an additional group of 73 children from the UK and 47 children from the United States, none of whom had yet begun strong arthritis treatments at the time of sampling.

Key findings include:

• Five specific genes were found to be strong predictors of methotrexate treatment response.
• This gene signature could be detected via a simple blood test, potentially before any medication is given.
• The study tracked participants over a 6-month period, providing a robust view of clinical outcomes.

According to lead investigator Professor Lucy Wedderburn (UCL/GOSH):
“Choosing the right treatment for a child with JIA is challenging. While MTX is effective for many, it doesn’t work for all. Biomarkers like these can help us personalize treatment decisions and avoid unnecessary delays.”

This research holds potential to:

• Reduce trial-and-error prescribing in pediatric arthritis care
• Minimize unnecessary side effects from ineffective treatments
• Accelerate time to disease control, improving long-term joint health and quality of life

The identification of this interferon gene signature represents a significant stride toward more targeted, effective treatment strategies for children living with juvenile arthritis. It underscores the value of genomic data and precision medicine approaches in clinical research for pediatric autoimmune diseases.

As efforts to validate and integrate this test into routine clinical practice continue, this breakthrough may soon help physicians make faster, data-informed decisions—offering children and families a clearer path to relief.

Citation:
Kartawinata M, et al. Identification and validation of interferon-driven gene signature as a predictor of response to methotrexate in juvenile idiopathic arthritis. Annals of the Rheumatic Diseases. 2025. DOI: 10.1016/j.ard.2025.03.007

Myra Fonville

Myra Fonville is the Executive Editor of Interim Visits magazine.  Myra is a former pharmacist who has worked in the clinical research industry for the past 28 years.  She brings a wealth of knowledge about pharmacy, pharmaceuticals and clinical research.  Myra is very passionate about diversity and health equity which is one of the primary reasons Interim Visits is educating the public about the importance of clinical trials.